| abstract |
The object of the present invention is the provision of novel compounds which may be used for the treatment of diseases, especially cardiovascular and haematological diseases. Hereinafter, compounds which act as specific inhibitors of HIF-prolyl-4-hydroxylases and which, due to this specific mechanism of action in vivo, cause the induction of HIF target genes such as as for example, erythropoietin and the biological processes thus caused, such as, for example, erythropoesis after parenteral or oral administration. The object of the present invention are compounds of the general formula (1), wherein A represents OH or N, R 13 represents a substituent selected from the (C 1 -C 6) alkyl, trifluoromethyl, halogen, cyano, nitro, hydroxy, (C 1 -C 6 -) alkoxy, amine, (C 1 -C 6) alkoxycarbonyl, hydroxycarbonyl and -C (= O) -NH-R 4 R 2 represents a substituent selected from the halogen, cyano, nitro, (C 1 -C 6) alkyl, trifluoromethyl, hydroxy (C 1 -C 6) alkoxy, trifluoromethoxy, amine, hydroxycarbonyl and -C (= O) -NH-R 8 = 8, m represents the number 0, 1 or 2, n represents the number 0, 1, 2 or 3, where in the case of R 1 or occur several times, their meanings in each case may be the same or different and R3 represents hydrogen, (C1-C6) -alkyl or (03-07) -cycloalkyl, as well as their salts, solvates and solvates of salts. |